文献速递乳房整形与再造

红乳综合征何去何从?:红乳综合征发病率随时间变化的系统综述

Red Breast Syndrome-Where Has It Gone?: A Systematic Review of Red Breast Syndrome Incidence Overtime.
PubMed 文献 · Ann Plast Surg · 2024-11-12

该系统综述分析2009年至2023年48项回顾性队列研究(n=6251),评估脱细胞真皮基质用于植入物乳房再造时红乳综合征的发病率趋势。未纳入先前综述的35项研究报告平均发病率为2.88%,加权平均为3.22%;红乳综合征报告发病率从2009年上升至2016-2017年峰值,之后持续下降至2022年。作者认为下降可能与ADM制备实践改变、ADM品牌变化及诊断分类改进有关,但尚无管理共识。

要点

  • 2009至2023年48项回顾性队列研究(n=6251)报告红乳综合征发病率呈先升后降趋势。
  • 未纳入先前综述的35项研究(n=5246)红乳综合征平均发病率2.88%,加权平均3.22%。
  • 红乳综合征报告发病率2016-2017年达峰后持续下降至2022年,但尚无管理共识。

核心结论

  • 红乳综合征发病率自2009年首次出现以来在既往研究和系统综述中波动显著,2018年以来报告发病率持续下降,基于近期报告研究的真实加权发病率为3.22%。
  • 尽管诊断标准更严格,红乳综合征的管理共识尚未建立。

研究设计与样本

  • 系统综述,2023年7月进行文献检索,分析脱细胞真皮基质用于植入物乳房再造的回顾性队列研究中红乳综合征发病率。
  • 遵循PRISMA指南,采用MINORS标准评估研究质量。
  • 共纳入48项研究(n=6251),其中35项来自2017至2023年的研究未被先前系统综述纳入(n=5246)。

主要发现

  • 2009至2023年48项研究(n=6251)符合纳入标准,其中35项来自2017至2023年的研究未被先前系统综述纳入(n=5246)。
  • 未纳入先前综述的研究中红乳综合征平均发病率为2.88%,加权平均为3.22%。
  • 红乳综合征报告发病率从2009年起上升,2016至2017年间达峰,之后持续下降至2022年。
  • 26项研究发表于2016至2019年。

关键数值与推荐

  • 红乳综合征报告发病率范围为7%-9%。
  • 未纳入先前综述的研究中红乳综合征平均发病率为2.88%,加权平均为3.22%。

临床怎么用

  • 作者认为红乳综合征发病率下降的可能原因包括ADM制备实践改变、用于植入物乳房再造的ADM品牌变化以及红乳综合征与蜂窝织炎/感染分类的改进。
  • 作者指出尽管诊断标准更严格,红乳综合征的管理共识尚未建立。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Red breast syndrome (RBS) has been noted in past literature as a possible complication of implant-based breast reconstruction (IBBR) with the use of acellular dermal matrices (ADMs). Since its first appearance in 2009, RBS has drawn growing medical attention with reported incidence ranging from 7%-9%. There has been a noted decrease in the emergence of RBS despite its inclusion among the analyzed complications in a number of studies. This systematic review aims to evaluate the trend in reported RBS incidence over time and appropriately determine an accurate incidence of RBS from reported literature since the emergence of the phenomena. METHODS: A systematic literature review was performed in July 2023 that analyzed the incidence of RBS among retrospective cohort studies on complication rates of IBBR with ADM. Patient demographics, RBS incidence rates, and all-cause complications were captured. The review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines and Methodological Index for Nonrandomized Studies criteria was used to assess study quality. RESULTS: From 2009 to 2023, a total of 48 studies (n = 6251) met inclusion criteria of which 35 studies from 2017 to 2023 were not already included in a prior systematic review (n = 5246). The mean incidence of RBS in the unreported studies was 2.88% with a weighted mean of 3.22%. Analysis of the trend in RBS over time shows an increasing reported incidence rate from 2009 with a peak in incidence between 2016 and 2017, followed by a steady decline through 2022. Twenty-six of the studies were published from 2016 to 2019. CONCLUSIONS: The incidence of RBS among prior studies and systematic reviews has fluctuated significantly since its initial emergence in 2009. Reported incidence rates have been on the decline since 2018 with a true weighted incidence of 3.22% from analysis of recent reported studies. Potential causes for the decline in incidence include practice changes in ADM preparation, changes in the ADM brand used for IBBR, and improved categorization of RBS compared to cellulitis/infection. Despite more robust criteria for diagnosis, no consensus for management has yet been established.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Navarro Y, Makarewicz N, Hinson C, et al. Red Breast Syndrome-Where Has It Gone?: A Systematic Review of Red Breast Syndrome Incidence Overtime. Ann Plast Surg. 2024. PMID: 39841901. doi:10.1097/SAP.0000000000004151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。